Maxcyte (MXCT) Net Cash Flow (2020 - 2026)

Maxcyte (MXCT) has 7 years of Net Cash Flow data on file, last reported at -$5.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 22.43% year-over-year to -$5.5 million in Q1 2026; TTM through Mar 2026 was -$8.8 million, a 877.11% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, up 58.01% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$5.5 million, down from $7.1 million in the prior quarter.
• Over the last five years, Net Cash Flow for MXCT reached as high as $192.0 million in Q1 2022 and fell as low as -$130.6 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$2.0 million across 5 years, with a median of -$4.5 million in 2025.
• On a YoY basis, Net Cash Flow climbed as much as 220.27% in 2022 and fell as far as 406.95% in 2022.
• Year by year, Net Cash Flow stood at -$32.0 million in 2022, then jumped by 91.66% to -$2.7 million in 2023, then plunged by 240.49% to -$9.1 million in 2024, then jumped by 178.16% to $7.1 million in 2025, then plunged by 177.66% to -$5.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$5.5 million in Q1 2026, $7.1 million in Q4 2025, and -$2.3 million in Q3 2025.